Want to join the conversation?
Fresenius Kabi & $BDX said that they both have signed a 10-year supply & distribution agreement under which Fresenius Kabi will supply $BDX with intravenous solutions. Both $BDX & Fresenius Kabi to offer a range of IV solutions in the U.S. beginning in 2016. Financial terms of the transactions were not disclosed.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.